Entera Bio Ltd. (ENTX): Total Assets
$15.99M
As of 2025-12-31
$19.48M
As of 2026-06-30
+6.8%
3-year compound annual growth
+10.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.99M | +70.3% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $9.39M | -20.2% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $11.77M | -10.4% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $13.13M | -49.5% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $25.99M | +167.3% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $9.72M | n/a | 2022-03-08, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $15.99M | +70.3% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $32.35M | -18.2% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $51.22M | -47.6% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $5.78M | -32.8% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $7.39M | -49.6% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $1.64M | +195.7% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $93.00M | -4.0% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $7.81M | +17.1% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $61.88M | -36.3% |
Compare ENTX, INMB, SNTI, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗